-+ 0.00%
-+ 0.00%
-+ 0.00%

D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $9 Price Target

Benzinga·02/18/2025 12:09:16
Listen to the news
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $9 price target.